Free Trial

CytomX Therapeutics (CTMX) Competitors

CytomX Therapeutics logo
$2.13 +0.09 (+4.41%)
Closing price 04:00 PM Eastern
Extended Trading
$2.11 -0.02 (-0.94%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CTMX vs. AVBP, TRVI, PHAR, DAWN, DNTH, IOVA, EOLS, ABUS, AKBA, and ZYBT

Should you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), Iovance Biotherapeutics (IOVA), Evolus (EOLS), Arbutus Biopharma (ABUS), Akebia Therapeutics (AKBA), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

CytomX Therapeutics vs.

ArriVent BioPharma (NASDAQ:AVBP) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

ArriVent BioPharma currently has a consensus price target of $39.29, indicating a potential upside of 90.43%. CytomX Therapeutics has a consensus price target of $5.33, indicating a potential upside of 150.39%. Given CytomX Therapeutics' higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than ArriVent BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ArriVent BioPharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
CytomX Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

ArriVent BioPharma has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

CytomX Therapeutics has a net margin of 10.96% compared to ArriVent BioPharma's net margin of 0.00%. CytomX Therapeutics' return on equity of -41.47% beat ArriVent BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ArriVent BioPharmaN/A -43.89% -29.67%
CytomX Therapeutics 10.96%-41.47%8.11%

In the previous week, CytomX Therapeutics had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 17 mentions for CytomX Therapeutics and 14 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.54 beat CytomX Therapeutics' score of 0.36 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ArriVent BioPharma
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
CytomX Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

CytomX Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ArriVent BioPharmaN/AN/A-$69.33M-$3.77-5.47
CytomX Therapeutics$147.56M1.16-$570K$0.484.44

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 7.0% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CytomX Therapeutics received 356 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 95.83% of users gave ArriVent BioPharma an outperform vote while only 65.46% of users gave CytomX Therapeutics an outperform vote.

CompanyUnderperformOutperform
ArriVent BioPharmaOutperform Votes
23
95.83%
Underperform Votes
1
4.17%
CytomX TherapeuticsOutperform Votes
379
65.46%
Underperform Votes
200
34.54%

Summary

CytomX Therapeutics beats ArriVent BioPharma on 12 of the 18 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTMX vs. The Competition

MetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$171.72M$6.48B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio12.539.0626.7119.71
Price / Sales1.16251.50386.13120.55
Price / CashN/A65.8538.2534.62
Price / Book-3.006.456.774.50
Net Income-$570,000.00$143.98M$3.23B$248.22M
7 Day Performance6.50%2.41%1.80%0.56%
1 Month Performance189.36%4.56%11.10%13.17%
1 Year Performance13.30%-2.67%17.11%7.30%

CytomX Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTMX
CytomX Therapeutics
4.2271 of 5 stars
$2.13
+4.4%
$5.33
+150.4%
+9.1%$164.47M$147.56M12.53170Analyst Revision
AVBP
ArriVent BioPharma
1.0187 of 5 stars
$19.99
-0.8%
$39.00
+95.1%
+2.6%$680.56MN/A-7.7840Analyst Forecast
TRVI
Trevi Therapeutics
3.5963 of 5 stars
$6.70
+1.5%
$17.56
+162.1%
+126.4%$669.28MN/A-15.2320News Coverage
Positive News
Analyst Forecast
PHAR
Pharming Group
1.7842 of 5 stars
$9.81
-2.2%
$30.00
+206.0%
+11.2%$667.04M$297.20M-37.71280Gap Down
DAWN
Day One Biopharmaceuticals
2.7495 of 5 stars
$6.58
+2.0%
$30.57
+364.6%
-57.5%$666.96M$161.92M-6.3960
DNTH
Dianthus Therapeutics
1.2799 of 5 stars
$20.08
+2.5%
$54.33
+170.6%
-23.7%$645.09M$6.24M-8.0380
IOVA
Iovance Biotherapeutics
4.4338 of 5 stars
$1.93
+10.3%
$14.80
+666.8%
-83.0%$644.49M$212.68M-1.30500Trending News
High Trading Volume
EOLS
Evolus
3.611 of 5 stars
$9.98
+1.8%
$23.75
+138.0%
-27.1%$643.42M$266.27M-10.97170Gap Up
High Trading Volume
ABUS
Arbutus Biopharma
2.0539 of 5 stars
$3.35
+3.7%
$5.50
+64.2%
-1.2%$641.46M$6.17M-7.7990News Coverage
Gap Up
AKBA
Akebia Therapeutics
4.2848 of 5 stars
$2.43
-4.7%
$6.63
+172.6%
+148.7%$636.14M$160.18M-10.56430High Trading Volume
ZYBT
Zhengye Biotechnology
N/A$13.43
+30.3%
N/AN/A$633.44M$189.75M0.00278

Related Companies and Tools


This page (NASDAQ:CTMX) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners